PL413428A1 - Derivative of benzothiophene piperazine and its applications - Google Patents
Derivative of benzothiophene piperazine and its applicationsInfo
- Publication number
- PL413428A1 PL413428A1 PL413428A PL41342815A PL413428A1 PL 413428 A1 PL413428 A1 PL 413428A1 PL 413428 A PL413428 A PL 413428A PL 41342815 A PL41342815 A PL 41342815A PL 413428 A1 PL413428 A1 PL 413428A1
- Authority
- PL
- Poland
- Prior art keywords
- disease
- derivative
- disorders
- benzothiophene
- piperazine
- Prior art date
Links
- YURASQWGJHLNNE-UHFFFAOYSA-N 1-benzothiophene;piperazine Chemical class C1CNCCN1.C1=CC=C2SC=CC2=C1 YURASQWGJHLNNE-UHFFFAOYSA-N 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- VFNQSWCRWMWXHD-UHFFFAOYSA-N C(CN1)NC2=C1SC1=C2C=CC=C1 Chemical class C(CN1)NC2=C1SC1=C2C=CC=C1 VFNQSWCRWMWXHD-UHFFFAOYSA-N 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- NYMDGCCOKHMPDH-UHFFFAOYSA-N O=S(C1=CN=CC2=CC=CC=C12)(NCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2)=O Chemical compound O=S(C1=CN=CC2=CC=CC=C12)(NCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2)=O NYMDGCCOKHMPDH-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Ujawniono nową pochodną benzotiofenopiperazyny o nazwie [3-(4-benzo[b]tiofen-4-ylo-piperazin-1-ylo)-propylo]izochinolino-4-sulfonamid, która może być wykorzystywana jako modulator dopaminy i serotoniny, zwłaszcza jako środek terapeutyczny w leczeniu chorób ośrodkowego układu nerwowego, włączając depresję, manię, zaburzenia nastroju, zaburzenia lękowe, schizofrenię, zaburzenia związane z przyjmowaniem pokarmu, ADHD. Ponadto, ujawniony związek ma szerokie spektrum zastosowań jako środek terapeutyczny w chorobie Alzheimera, chorobie Parkinsona, chorobie Huntingtona, zespole Tourreta, autyzmie, napadach padaczkowych, lekozależności, otyłości, nie wykazując działań niepożądanych (sedacji) i wysokim bezpieczeństwie.A new benzothiophenopiperazine derivative named [3- (4-benzo [b] thiophen-4-yl-piperazin-1-yl) -propyl] isoquinoline-4-sulfonamide has been disclosed, which can be used as a dopamine and serotonin modulator, especially as an agent therapeutic in the treatment of central nervous system diseases, including depression, mania, mood disorders, anxiety disorders, schizophrenia, food related disorders, ADHD. In addition, the disclosed compound has a wide spectrum of uses as a therapeutic agent in Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourret syndrome, autism, epileptic seizures, drug dependence, obesity, without side effects (sedation) and high safety.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL413428A PL231170B1 (en) | 2015-08-07 | 2015-08-07 | Derivative of benzothiophene piperazine and its applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL413428A PL231170B1 (en) | 2015-08-07 | 2015-08-07 | Derivative of benzothiophene piperazine and its applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL413428A1 true PL413428A1 (en) | 2017-02-13 |
| PL231170B1 PL231170B1 (en) | 2019-01-31 |
Family
ID=57965322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL413428A PL231170B1 (en) | 2015-08-07 | 2015-08-07 | Derivative of benzothiophene piperazine and its applications |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL231170B1 (en) |
-
2015
- 2015-08-07 PL PL413428A patent/PL231170B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL231170B1 (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003731A1 (en) | Compounds derived from carboxamide; pharmaceutical composition that includes them, and their use as inhibitors of phosphodiesterase type 10a (pde10a) for the treatment of CNS disorders, schizophrenia, cognitive dysfunction related to schizophrenia, bipolar disorders, depression, cognitive dysfunction, cognitive disorders, behavioral disorders associated with Alzheimer's disease, obesity, huntington's disease and anxiety. | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| CL2015000096A1 (en) | Compounds derived from 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta [a] naphthalenes, phosphodiestearase 2 and / or 10 inhibitors; pharmaceutical composition; and its use for prevention or treatment of diseases of the nervous system, such as cognitive deficiency, dementia, anxiety disorders, enf. from Alzheimer, enf. from parkinson, others | |
| MX2020013099A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands. | |
| CL2016001595A1 (en) | Gpr6 tetrahydropyridyrazine modulators. | |
| MX2019000588A (en) | Somatostatin modulators and uses thereof. | |
| CL2017002223A1 (en) | Methods for the treatment of abnormal involuntary movement disorders | |
| GEP20227446B (en) | New catecholamine prodrugs for use in treatment of parkinson's disease | |
| BR112015023349A2 (en) | compound, pharmaceutical composition, and method of treating a disease, health condition or disorder | |
| DOP2017000013A (en) | PREPARATION PROCEDURE FOR REPLACED 5-FLUORO-1H-PIRAZOLOPIRIDINAS | |
| EA201791874A1 (en) | FLUORINATED INHIBITORS OF LYZYLOXIDE-LIKE ENZYME-2 AND THEIR APPLICATION | |
| CL2012003178A1 (en) | Compounds derived from unsaturated nitrogen heterocycles or their pharmaceutically acceptable salts, such as pde10 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of diseases such as psychosis, parkinson's disease, depression, mood disorders and dementia. | |
| CL2015002122A1 (en) | Modulators of nmda receptors of spiro-lactam and their uses. | |
| EA201691447A1 (en) | 2-AMINO-3,5,5-TRIFTOR-3,4,5,6-TETRAGIDROPYRIDINES AS BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| MX391725B (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS. | |
| EA201400969A1 (en) | NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF PARKINSON'S Disease | |
| GEP20156339B (en) | New co-crystals of agomelatine, process for their preparation and pharmaceutical compositions containing them | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| UY36178A (en) | NOVEDOSOS DERIVED FROM HETEROARIL-BUTANOIC ACID | |
| UA109260C2 (en) | CHROMON DERIVATIVES, METHODS OF THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | |
| EP2826793A4 (en) | PROCESS FOR THE PREPARATION OF CONJUGATED DIENE POLYMER, COMPOSITION CONTAINING POLYMER, AND TIRE COMPRISING THE COMPOSITION | |
| MA39914A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| GT201400242A (en) | "NEW COMPOUNDS OF PIRAZOL" | |
| MX2015008733A (en) | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders. | |
| CL2016002321A1 (en) | Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders. |